Autres langues Aptamer Group plc

Actions

APTA

GB00BNRRP542

Temps Différé London S.E. Autres places de cotation 10:53:12 23/05/2024			Varia. 5j.	Varia. 1 janv.
0,792 ^GBX	+2,19 %		+9,24 %	-31,13 %

22/05	Aptamer Group s'associe à Timser pour le premier test sanguin de dépistage du cancer du col de l'utérus	MT
22/05	Les actions d'Aptamer en hausse suite à la signature d'un contrat de 465 000 GBP avec Timser pour le traitement du cancer du col de l'utérus	AN

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aptamer Group Teams Up with Timser for First-ever Cervical Cancer Blood Test	22/05
Aptamer shares up on GBP465,000 cervical cancer contract with Timser	22/05
Aptamer says sales pipeline "strong" as reports strategic headway	13/05
EARNINGS AND TRADING: Zenova's Kitemark award; Carnival's eyes savings	22/04
Aptamer inks new Optimer+ transplant rejection therapy partnership	18/04
Aptamer Group, Kairos Biotech Team Up to Improve Transplant Success	18/04
Aptamer Group Files Patent Application for Optimer Binders	08/04
Aptamer submits patent application for Optimer binders	08/04
EARNINGS AND TRADING: Arbuthnot ups payout as profit more than doubles	28/03
Aptamer Group plc Reports Earnings Results for the Half Year Ended December 31, 2023	28/03
Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial	25/03
Aptamer shares jump on successful Unilever contract progression	11/03
Aptamer Group, Unilever Prepare to Patent Optimers Developed Under Partnership	11/03
Aptamer says new Optimer+ delivers improved results	27/02
Aptamer Group plc Announces R&D Progress on New Optimer®? + Platform	27/02
Aptamer and Neuro-Bio begin Alzheimer's test development second phase	22/02
Aptamer Group, Neuro-Bio Enter Second Phase of Partnership for Alzheimer's Flow Test Development	22/02
Aptamer shares plunge as half-year revenue to fall by 70%	05/02
Aptamer Group plc Provides Revenue Guidance for the First Half of the Fiscal Year 2024	05/02
Zentek Announces "Positive" Therapeutic Results Achieved by Triera Biosciences for C19HBA	30/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aptamer Group plc

Actions

APTA

GB00BNRRP542

Autres langues

Filtres